niacinamide has been researched along with Biliary Cirrhosis in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " As the multikinase inhibitor sorafenib inhibits ERK, we tested the effect of sorafenib on haemodynamics and dysregulated vascular Rho kinase in rats with secondary biliary cirrhosis." | 7.75 | Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. ( Heller, J; Hennenberg, M; Kohistani, AZ; Sauerbruch, T; Stark, C; Trebicka, J, 2009) |
| "HPS (hepatopulmonary syndrome) is characterized by oxygen desaturation in patients with chronic liver disease." | 5.39 | Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. ( Chang, CC; Chuang, CL; Hsieh, HG; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS, 2013) |
| " This leads to the decrease in intrahepatic vascular resistance, but also to liver damage in the dosage we used." | 5.37 | Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. ( Fischer, HP; Granzow, M; Heller, J; Hennenberg, M; Klein, S; Kohistani, Z; Körner, C; Krämer, B; Nischalke, HD; Sauerbruch, T; Stark, C; Trebicka, J, 2011) |
| " As the multikinase inhibitor sorafenib inhibits ERK, we tested the effect of sorafenib on haemodynamics and dysregulated vascular Rho kinase in rats with secondary biliary cirrhosis." | 3.75 | Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. ( Heller, J; Hennenberg, M; Kohistani, AZ; Sauerbruch, T; Stark, C; Trebicka, J, 2009) |
| "The occurrence of hepatocellular carcinoma is about 3-15 % in patients with alcoholic liver disease." | 2.46 | [Hepatocellular carcinoma: occurrence, risk factors, biomarkers]. ( Fehér, J; Lengyel, G, 2010) |
| "HPS (hepatopulmonary syndrome) is characterized by oxygen desaturation in patients with chronic liver disease." | 1.39 | Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. ( Chang, CC; Chuang, CL; Hsieh, HG; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS, 2013) |
| " This leads to the decrease in intrahepatic vascular resistance, but also to liver damage in the dosage we used." | 1.37 | Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. ( Fischer, HP; Granzow, M; Heller, J; Hennenberg, M; Klein, S; Kohistani, Z; Körner, C; Krämer, B; Nischalke, HD; Sauerbruch, T; Stark, C; Trebicka, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hennenberg, M | 2 |
| Trebicka, J | 2 |
| Stark, C | 2 |
| Kohistani, AZ | 1 |
| Heller, J | 2 |
| Sauerbruch, T | 2 |
| Fehér, J | 1 |
| Lengyel, G | 1 |
| Kohistani, Z | 1 |
| Nischalke, HD | 1 |
| Krämer, B | 1 |
| Körner, C | 1 |
| Klein, S | 1 |
| Granzow, M | 1 |
| Fischer, HP | 1 |
| Chang, CC | 1 |
| Chuang, CL | 1 |
| Lee, FY | 1 |
| Wang, SS | 1 |
| Lin, HC | 1 |
| Huang, HC | 1 |
| Teng, TH | 1 |
| Hsu, SJ | 1 |
| Hsieh, HG | 1 |
| Lee, SD | 1 |
| Rollier, R | 1 |
| Rollier, M | 1 |
1 review available for niacinamide and Biliary Cirrhosis
| Article | Year |
|---|---|
[Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Copper; Deve | 2010 |
4 other studies available for niacinamide and Biliary Cirrhosis
| Article | Year |
|---|---|
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.
Topics: Animals; Aorta; Benzenesulfonates; Blotting, Western; Hypertension, Portal; Liver; Liver Cirrhosis, | 2009 |
Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis.
Topics: Actins; Animals; Apoptosis; Benzenesulfonates; Caspase 3; Colorimetry; DNA Fragmentation; Hepatic St | 2011 |
Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis.
Topics: Animals; Benzenesulfonates; Common Bile Duct; Disease Models, Animal; Hemodynamics; Hepatopulmonary | 2013 |
[Treatment of lepromatous leprosy by ethionamide].
Topics: Adolescent; Adult; Age Factors; Aged; Avitaminosis; Child; Ethionamide; Female; Gastrointestinal Dis | 1972 |